Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NG01 in Secondary Progressive Multiple Sclerosis
NCT06961383Phase 2Not yet recruiting
- Sponsor
- NeuroGenesis
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Stem Cell Therapies, Adoptive Cell Transfer
- Countries
- 2
01
Overview
A Phase 2 trial of MSC-NG01 in secondary-progressive multiple sclerosis (SPMS), sponsored by NeuroGenesis. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
MSC-NG01
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT06961383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961383.